China Orders Ban On Fenfluramine Weight-Loss Drug
This article was originally published in PharmAsia News
Chinese authorities have issued a ban on fenfluramine hydrochloride, a drug banned in the United States and Europe since 2000 because of heart and pulmonary risks. China's State FDA ordered the ban after it decided the risks of side effects associated with bloody urine and nausea outweighed the benefits of the drug for losing weight. Producers were ordered to recall the drugs and purchasers are to receive refunds. (Click here for more
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.